DVAXDynavax Technologies Corporation

DVAX Stock Price, Valuation & Chart | Dynavax Technologies Corporation

$15.500+0.00 (+0.00%)

At close · 11 Feb 2026, 09:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic DVAX intrinsic value DVAX calculated fair value vs price

Overview Financials Dividends Ratios

DVAX Historical price chart

DVAX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.82B

PE Ratio-41.89

EPS-0.37

Trading Volume5.66M

Today's High/Low15.5/15.5

Dividend Yield0.00

52 Week High/Low15.73/9.2

Shares Outstanding117.42M

DVAX Financial Statement

DVAX Analyst ratings

DVAX Analysis & performance metrics

DVAX Company profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B,…

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant…

DVAX Management team

Name

Position

Donn Casale

Senior Vice President & Chief Commercial Officer

David F. NovackCOO

President & Chief Operating Officer

Kelly MacDonald CPACFO

Senior Vice President, Principal Accounting Officer & Chief Financial Officer

Jeff P. Coon

Senior Vice President & Chief Human Resources Officer

Dong Yu

Senior Vice President of Research

Paul Cox

Vice President of Investor Relations & Corporate Communications

John L. Slebir

Senior Vice President & General Counsel

Eric Frings

Vice President, Site Head & MD for Dynavax GmbH

Name

Position

Donn Casale

Senior Vice President & Chief Commercial Officer

David F. NovackCOO

President & Chief Operating Officer

Kelly MacDonald CPACFO

Senior Vice President, Principal Accounting Officer & Chief Financial Officer

Jeff P. Coon

Senior Vice President & Chief Human Resources Officer

Dong Yu

Senior Vice President of Research

Paul Cox

Vice President of Investor Relations & Corporate Communications

John L. Slebir

Senior Vice President & General Counsel

Eric Frings

Vice President, Site Head & MD for Dynavax GmbH

Management Team

Donn Casale

Senior Vice President & Chief Commercial Officer

David F. NovackCOO

President & Chief Operating Officer

Kelly MacDonald CPACFO

Senior Vice President, Principal Accounting Officer & Chief Financial Officer

Jeff P. Coon

Senior Vice President & Chief Human Resources Officer

Dong Yu

Senior Vice President of Research

Paul Cox

Vice President of Investor Relations & Corporate Communications

John L. Slebir

Senior Vice President & General Counsel

Eric Frings

Vice President, Site Head & MD for Dynavax GmbH

Management

Donn Casale

Senior Vice President & Chief Commercial Officer

David F. NovackCOO

President & Chief Operating Officer

Kelly MacDonald CPACFO

Senior Vice President, Principal Accounting Officer & Chief Financial Officer

Jeff P. Coon

Senior Vice President & Chief Human Resources Officer

Dong Yu

Senior Vice President of Research

Paul Cox

Vice President of Investor Relations & Corporate Communications

John L. Slebir

Senior Vice President & General Counsel

Eric Frings

Vice President, Site Head & MD for Dynavax GmbH

Total 8 executives

DVAX Frequently asked questions

What is Dynavax Technologies Corporation (DVAX) Stock Price?

Current stock price of Dynavax Technologies Corporation (DVAX) stock is $15.500. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Dynavax Technologies Corporation (DVAX) stock is 5.66M.

Last updated at 11 Feb 2026, 09:00 pm.

Why is the Dynavax Technologies Corporation (DVAX) stock price going up or down today?

The stock price of Dynavax Technologies Corporation (DVAX) can change with earnings, company news, and overall market sentiment. Dynavax Technologies Corporation operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Dynavax Technologies Corporation stock expensive at its current price?

Whether Dynavax Technologies Corporation looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for DVAX on this page is -41.89. EPS on this page is -0.37. Compare those figures with peers and growth expectations before deciding if the current Dynavax Technologies Corporation price is justified.

How has the stock price of Dynavax Technologies Corporation (DVAX) performed historically?

Historical performance for Dynavax Technologies Corporation (DVAX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how DVAX reacted to past earnings and market events.

Should I buy Dynavax Technologies Corporation (DVAX) stock, at this price?

Buying Dynavax Technologies Corporation (DVAX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.